Kiniksa Pharmaceuticals International

KNSA · NASDAQ

$83.17+$3.69 (+4.64%)TodayMarket closed · Oct 20, 7:56 PM ET

Prev close $79.48

About KNSA

Kiniksa Pharmaceuticals International Plc is a commercial-stage biopharmaceutical company. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.

Employees: 366
Headquarters: London
Listed: May 24, 2018
Sector: Health Care
Industry: Biotechnology
Website: kiniksa.com

Leadership

Kiniksa Pharmaceuticals International executives
Name	Title	Since	Age
Sanjiv Patel	—	2015	53
Mark Ragosa	—	—	49
Eben Tessari	—	—	41
Ross Moat	—	—	42
John Paolini	—	—	58
Michael Megna	—	—	52
Felix Baker	—	—	54
Stephen Biggar	—	—	52
G. Bradley Cole	—	—	67
Richard Levy	—	—	65
Thomas Malley	—	—	54
Tracey McCain	—	—	55
Kimberly Popovits	—	—	64
Barry Quart	—	—	66

Revenue by product and region

Fiscal year ended Dec 31, 2024: $423.24M total revenue

By product

Product [Member]$417.03M98.5%
Joint operating activities with a collaborator or partner with shared risks and benefits.$189.00K0.0%

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.